跳至主要内容
临床试验/NCT02206867
NCT02206867已完成1 期

A Randomized, Double-Blind, Parallel-Group Clinical Study to Compare Pharmacokinetics, Safety and Tolerability of LBAL 40 mg With Humira® 40 mg After a Single Subcutaneous Administration in Healthy Male Volunteers

LG Life Sciences0 个研究点目标入组 116 人开始时间: 2014年8月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
116
主要终点
Maximum measured concentration of the analyte in serum

研究概览

简要总结

To compare PK, safety and tolerability of LBAL developed by LG Life Sciences Ltd. With those of Humira®.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 20-45 years old healthy males
  • Body mass index 19.0 ~ 28.0 kg/m2

排除标准

  • Diagnosis of current or latent tuberculosis (TB); history of severe active chronic or local infection including TB
  • Severe infection (e.g. sepsis) requiring admission or antibiotics treatment within four weeks prior to administration
  • Clinically relevant previous or concomitant disease including hepatic, renal, neurological, respiratory, gastrointestinal, endocrine, hematologic, oncologic, cardiovascular, urinary, musculoskeletal or psychiatric, autoimmune disease/disorders
  • Chronic or relevant acute infections. A negative result for human immunodeficiency virus (HIV), Hepatitis B (Hep B), and hepatitis C (Hep C) is required for participation (i.e. HIV Ab, HBsAg, HBcAb, HCV Ab)
  • Fever greater than 38.3℃ within a week prior to administration of study drug
  • Previous or current drug abuse

结局指标

主要结局

Maximum measured concentration of the analyte in serum

时间窗: 0 to 65 days

Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity

时间窗: 0 to 65 days

次要结局

未报告次要终点

研究者

发起方
LG Life Sciences
申办方类型
Industry
责任方
Sponsor

相似试验